Get the Stockscreener App
5.37
9.60%
-0.57
After Hours:
5.30
-0.07
-1.30%
Galectin Therapeutics Inc stock is traded at $5.37, with a volume of 1.20M.
It is down -9.60% in the last 24 hours and up +42.44% over the past month.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
See More
Previous Close:
$5.94
Open:
$6.49
24h Volume:
1.20M
Relative Volume:
1.82
Market Cap:
$344.00M
Revenue:
-
Net Income/Loss:
$-45.08M
P/E Ratio:
-7.3562
EPS:
-0.73
Net Cash Flow:
$-33.68M
1W Performance:
+16.74%
1M Performance:
+42.44%
6M Performance:
+214.04%
1Y Performance:
+98.15%
1-Day Range:
$5.31
$6.55
1-Week Range:
$4.50
$6.55
52-Week Range:
$0.726
$6.55
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
5.37 | 320.30M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Resumed | H.C. Wainwright | Buy |
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Is Galectin Therapeutics Inc. stock entering bullish territory2025 Stock Rankings & Weekly Watchlist of Top Performers - Newser
What Fibonacci levels say about Galectin Therapeutics Inc. reboundMarket Weekly Review & Step-by-Step Trade Execution Guides - Newser
Galectin Therapeutics Inc. (GALT) Is Up 7.48% in One Week: What You Should Know - sharewise.com
Will Galectin Therapeutics Inc. stock recover after recent dropRate Hike & Safe Entry Point Alerts - Newser
What technical models suggest about Galectin Therapeutics Inc.’s comebackTrade Signal Summary & Expert Approved Momentum Ideas - Newser
Is Galectin Therapeutics Inc. building a consolidation baseMarket Performance Summary & Low Risk High Win Rate Stock Picks - Newser
Chart based analysis of Galectin Therapeutics Inc. trendsQuarterly Trade Review & Long-Term Growth Portfolio Plans - Newser
Using data tools to time your Galectin Therapeutics Inc. exit2025 Top Gainers & Technical Pattern Based Signals - Newser
Analyzing recovery setups for Galectin Therapeutics Inc. investorsTrend Reversal & Weekly High Conviction Ideas - Newser
Galectin Therapeutics Inc. (NASDAQ:GALT) Surges 27%; Individual Investors Who Own 53% Shares Profited Along With Insiders - 富途牛牛
Tools to monitor Galectin Therapeutics Inc. recovery probabilityTrade Volume Summary & Reliable Volume Spike Trade Alerts - Newser
Multi factor analysis applied to Galectin Therapeutics Inc.Quarterly Profit Report & Real-Time Volume Analysis - Newser
How to manage a losing position in Galectin Therapeutics Inc.Market Trend Review & Reliable Volume Spike Alerts - Newser
Can a trend reversal in Galectin Therapeutics Inc. lead to recoveryJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Does Galectin Therapeutics Inc. show high probability of reboundForecast Cut & Stock Portfolio Risk Control - Newser
HighTower Advisors LLC Raises Holdings in Galectin Therapeutics Inc. $GALT - MarketBeat
Should you hold or exit Galectin Therapeutics Inc. nowJuly 2025 Action & Weekly Return Optimization Alerts - Newser
Comparing Galectin Therapeutics Inc. in custom built stock radarsQuarterly Investment Review & Real-Time Buy Zone Alerts - Newser
How to monitor Galectin Therapeutics Inc. with trend dashboards2025 Retail Activity & Low Drawdown Trading Techniques - Newser
Real time pattern detection on Galectin Therapeutics Inc. stockEarnings Summary Report & Safe Capital Growth Trade Ideas - Newser
Galectin Therapeutics Inc. stock chart pattern explained2025 Key Highlights & Consistent Return Investment Signals - Newser
Galectin Therapeutics Stock Hits 52-Week High On Biomarker Update And MASH Trial Momentum - RTTNews
Will Galectin Therapeutics Inc. benefit from macro trendsJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - Newser
Using data models to predict Galectin Therapeutics Inc. stock movementPortfolio Value Report & Consistent Income Trade Recommendations - Newser
Volume spikes in Galectin Therapeutics Inc. stock – what they meanGDP Growth & Safe Capital Growth Plans - Newser
Can Galectin Therapeutics Inc. recover in the next quarterPortfolio Profit Report & Expert Verified Stock Movement Alerts - Newser
Is Galectin Therapeutics Inc. a candidate for recovery playWeekly Stock Analysis & Technical Pattern Based Signals - Newser
Chart based exit strategy for Galectin Therapeutics Inc.Analyst Downgrade & Safe Capital Preservation Plans - Newser
Predicting Galectin Therapeutics Inc. trend using moving averagesWeekly Stock Recap & AI Driven Price Predictions - Newser
Why Galectin Therapeutics Inc. is moving todayJuly 2025 Big Picture & Safe Entry Point Identification - Newser
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):